Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age
Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M
Versant Ventures, Sticking With its Knitting, Raises $950M for Early Stage Biotechs
What Happened in Switzerland?